MMJ国际寻求林业发展局批准一种以大麻为基础的软凝胶治疗亨廷顿病。 MMJ International seeks FDA approval for a cannabis-based softgel to treat Huntington’s disease.

MMJ国际控股公司正在推进一个为亨廷顿病研制的以大麻为基础的软凝胶胶囊,可能得到林业发展局的批准。 MMJ International Holdings is advancing a cannabis-based softgel capsule developed for Huntington’s disease, with potential approval from the FDA. 该产品旨在提供精确剂量的大麻素,可为病人提供一种新的治疗选择。 The product, designed to deliver precise doses of cannabinoids, may offer a new treatment option for patients. 如果获得批准,它可以成为在管理神经退化性疾病症状方面的重大突破。 If approved, it could represent a significant breakthrough in managing symptoms of the neurodegenerative disorder. 该公司继续开展临床试验,以支持其提交监管文件。 The company continues to conduct clinical trials to support its regulatory submission.